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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 
























• This study found that severe 
outcomes for patients admitted 
to hospital with COVID-19 
infection can be assessed 
using machine learning-based 
models using readily available 
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• Randomised, double-blind 
trial of colchicine, an orally 
administered, anti-
inflammatory, in 4488 non-
hospitalised patients with 
COVID-19 
• The primary endpoint 
occurred in 4.7% of the 
patients in the colchicine 
group and 5.8% of those in 
the placebo group. odds 
ratio, 0.79; 95.1% 
confidence interval 0.61 to 
1.03; P=0.08 
• Among non-hospitalized 
patients with COVID-19, 
colchicine reduces the 













• Determining which SARS-
CoV-2 mutations escape key 
antibodies is essential for 
assessing how mutations 
observed during viral 
surveillance may impact 
efficacy of antibody 
treatments for SARS-CoV-2 
• Here, authors have 
completely mapped 
mutations that escape three 
leading anti-SARS-CoV-2 
antibodies 
• Authors express their 
concern that so many 
escape mutations impose 
little cost on the receptor 
binding domain folding or 
receptor affinity and that 
some are already present in 
circulating SARS-CoV-2 
strains 
• This work will assist viral 
genomic surveillance by 
enabling immediate 
interpretation of the effects 

























The Lancet | 
Article 
• First known study 
to assess the effect 
of two different 
adjuvants (AS03 
and CPG/Alum) on 





technology in 151 
trial participants 
• Immune responses 
to the S-Trimer 
protein alone were 




antibody titres after 
two vaccinations  
• Responses were 
consistent with 
those recorded in 
the reference 
standard - a panel 
of convalescent 
serum samples 
from patients with 
COVID-19 
• Both SCB-2019 
adjuvanted 
formulations, which 
are stable when 
stored at 2-8oC, 
were generally well 


















either the Wuhan 
reference strain or 
the B.1.1.7 lineage 
spike protein were 







40 participants who 
were vaccinated in 
a previously 




• Results suggest 
that the B.1.1.7 




• These data 
suggest that the 
BioNTech-Pfizer 
vaccine will protect 
against the “UK 
variant” 


















• This review highlights 




mortality in COVID-19 
and summarises the 
consequences of SARS-
CoV-2 infection for organ 
function and risk of 
NCDs 
• Discusses data 
indicating that the 
COVID-19 pandemic 
could have serious 
consequences for the 
obesity epidemic 
• Proposes strategies, 
particularly during the 
COVID-19 pandemic, for 
the prevention and 
treatment of obesity and 
impaired metabolic 
health on a clinical and 
population, given obesity 
and impaired metabolic 

























• A community resilience 
approach frames epidemic 
shocks more holistically 
and from the perspectives 
of a whole system 
• A resilience framework 
offers the opportunity to 
build existing capacities to 
manage health, social, 
psychosocial and 
economic impacts of an 
epidemic making the 
resilience approach more 
localised, adaptable, and 
sustainable in the long-
term 
• This brief presents 
considerations for how 
health and humanitarian 
practitioners can support 
communities to respond to 
and recover from COVID-



















• Using the COVID-19 
pandemic as a case study, 
here authors 
operationalise a contextual 
framework on behaviour 
adoption during diverse 
public health emergencies 
to demonstrate how three 
approaches, top-down, 
intermediary and bottom-
up, differ in terms of their 
implementation, underlying 
drivers of action, 
enforcement, reach and 
uptake 
• Blended strategies that 
include all three 
approaches can help 




important even when safe 
and effective vaccines are 
widely available 
• This contextual framework 
can inform the design, 
implementation, tracking 
and evaluation of 
comprehensive public 
health and social 
measures during health 
emergencies 






















• Differences in how 
leaders address the 
pandemic through public 
messages have practical 
implications for building 
trust and an effective 
response within a 
country  
• Here an analysis of 
speeches made by 20 
heads of government 
from around the world 
find that five primary 
themes emerged across 
a total of 122 speeches 
on COVID-19: 
economics and financial 






• Findings provide insight 
into the rhetorical tools 
and types of language 
used by different leaders 
and on differences in 
political leaders’ 
messages and priorities 
to inspire citizens’ 
adhesion to the social 




of response and recovery 
measures 
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type 
01.02.2021 Oxygen shortages bite in poorer countries 
battling Covid 
Financial Times | News 
01.02.2021 Blurring lines: between vaccine urgency in a 
pandemic and research and regulation ethics 
PLoS Blogs 
31.01.2021 Jeremy Farrar: Until we are all safe, no one s 
safe. Covid is a global problem 
The Guardian | Interview 
30.01.2021 SARS-CoV-2 serosurveys in low-income and 
middle-income countries 
The Lancet | Comment 
30.01.2021 WHO’s Covid warnings were not heeded. Now 
the world has a new chance to beat the virus 
The Observer | Opinion 
30.01.2021 Health and care workers are owed a better future  The Lancet | Editorial 
29.01.2021 Next-generation COVID-19 vaccines: here come 
the proteins 
The Lancet | Comment 
29.01.2021 SARS-CoV-2 evolution and vaccines: cause for 
concern? 
The Lancet Respiratory 
Medicine | Comment 
29.01.2021 COVID-19 rarely spreads through surfaces. So 
why are we still deep cleaning? 
Nature | News 
29.01.2021 Combating the COVID-19 infodemic: a three-
level approach for low and middle-income 
countries 
BMJ Global Health | 
Commentary 
29.01.2021 Novavax offers first evidence that COVID 
vaccines protect people against variants 
Nature | News 
29.01.2021 How to redesign COVID vaccines so they protect 
against variants 
Nature | News 
29.01.2021 J&J’s one-shot COVID vaccine offers hope for 
faster protection 
Nature | News 
28.01.2021 SARS-CoV-2 testing for public health use: cire 
principles and considerations for defined use 
settings 
The Lancet Global Health | 
Comment 
28.01.2021 Urgent needs of low-income and middle-income 
countries for COVID-19 vaccines and 
therapeutics 
The Lancet | Comment 
28.01.2021 ‘The country is falling apart’: Lebanon’s hospitals 
overwhelmed by Covid surge 
Financial Times | News 
27.01.2021 Is Africa wasting the pandemic-induced 
economic crisis? 
CGD | Blog 
25.01.2021 COVID-19 is a gendered crisis. Here’s what 
policymakers can do about it 
CGD | Blog  
23.01.2021  South Africa responds to new SARS-CoV-2 
variant 
The Lancet | World Report 
Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 
 29.01.2021  The selection 
and use of 
essential in vitro 
diagnostics – 




• WHO released the third edition of 
its Model List of Essential In Vitro 
Diagnostics (EDL). This edition 
includes WHO-recommended 
Covid-19 tests (nucleic acid as 
well as antigen detection tests) 






• This IDC report highlights that 
developing countries face 
disastrous healthcare setbacks 
including disruption to routine 
secondary 
impacts 
immunisation and treatment 
programmes 
• Tackling COVID-19 is diverting 
funding, exhausting staff, 
absorbing resources, and scaring 
off patients with other illnesses 
from accessing healthcare 
Jan 2021 Future at risk: 
the UK’s role in 
averting a global 





• Using data from UNICEF 
countries and other partners, 
along with projections on the 
potential indirect health impacts of 
COVID-19, this report examines 
the effects of the pandemic on 
essential life-saving services for 
mothers, newborns and children 
• Also, sets an agenda for action for 
the UK Government, and 
specifically FCDO, to deliver on 
ending preventable deaths and 
ensure opportunity for every child 
 
  
   
 
Dashboards & Trackers  












  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford Vaccine 
Trial 





US NIH   Our World in 
Data: C19 
Testing 





Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence      Our World in 
Data: COVID-
19 vaccinations  
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 




  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs 







Health Topics   Social 
Sciences 
WHO COVID-
19 pandemic  
Africa CDC Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 







  IDA 




































































Institute of Public 
Health 
    
COVID-19 
Digest 





Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The 
Lancet 
 HEART     




 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    




    
Our World in 
Data 




  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  












      
WorldPop           
Flowminder           





    
  
GISAID           
  
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during 
the COVID-19 
pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply 
chain resilience and 
global trade 
Webinar 1h CGD 
03.12.2020 More money for 
health services: What 
is the tole of PFM in 
the “new normal”? 




1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental 
wellbeing of 
community health 
workers on the 
COVID-19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the 




  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to 
promote sharing of 
experience and 
expertise around the 
maintenance of 
essential health 
services during (and 
after) the pandemic 
4-week 
discussion 
starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
Online event 1h30 CGD 
before we approve 
efficacious COVID-19 
vaccines 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 












Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours 
per week 




WHO Academy and 
WHO Info mobile 
applications 





Modelling and Policy 









11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 






5 sessions 1h 30 International Initiative 












online brief with Dr 
David Nabarro 














training for the 
coronavirus disease 
outbreak 

































6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 





of Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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